Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PetroChina Co Ltd
XBER:PC6
|
CN |
|
K
|
Kingsview Minerals Ltd
CNSX:KVM
|
CA |
|
P
|
Panora Gayrimenkul Yatirim Ortakligi AS
IST:PAGYO.E
|
TR |
|
N
|
NVC International Holdings Ltd
HKEX:2222
|
CN |
|
Garudafood Putra Putri Jaya Tbk PT
IDX:GOOD
|
ID |
|
Tripadvisor Inc
NASDAQ:TRIP
|
US |
|
U
|
UMS Neiken Group Bhd
KLSE:UMS
|
MY |
|
Witbe SA
PAR:ALWIT
|
FR |
|
Kingsoft Cloud Holdings Ltd
NASDAQ:KC
|
CN |
Molecular Partners AG
Research & Development
Molecular Partners AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Research & Development
-CHf38.4m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$284.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-37%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf105.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf94.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf10.7m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Research & Development?
Research & Development
-38.4m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Research & Development amounts to -38.4m CHF.
What is Molecular Partners AG's Research & Development growth rate?
Research & Development CAGR 5Y
6%
Over the last year, the Research & Development growth was 18%. The average annual Research & Development growth rates for Molecular Partners AG have been 7% over the past three years , 6% over the past five years .
